Publications
29
Citations
177
Est. group size
~3
Recurring co-author estimate
Active years
36
Publishing since 1991
Typically publishes in teams of ~9 · 11% small-team papers (≤3 authors) · across 9 venues
- Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database
Clinical Lung Cancer · 2026
- Considerations for Menstrual Suppression in Patients With Hematologic Malignancies
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2026
- Evaluation of modified gemcitabine/nab-paclitaxel schedules in first line therapy for advanced pancreatic cancer: MI-OPTS-2 study.
Journal of Clinical Oncology · 2026
- Continuous, maintenance or intermittent first line (1L) therapy for advanced pancreatic cancer (aPC): MI-OPTS-1 study.
Journal of Clinical Oncology · 2026
- Risk Factors for CRS and ICANS with Tarlatamab in Small Cell Lung Cancer and Associated Efficacy Outcomes: Insights from Clinical Practice
SSRN Electronic Journal · 2026
- Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice
European Journal of Cancer · 2026
- Corrigendum to “Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice” [Eur. J. Cancer 238 (May) (2026) 116686]
European Journal of Cancer · 2026
- Real-World Analysis of Adverse Events in Patients With Triple-Negative Breast Cancer Receiving Therapy per KEYNOTE-522
JCO Oncology Practice · 2026
- Biomarker testing for metastatic non-small cell lung cancer across Michigan Oncology Quality Consortium (MOQC) sites.
JCO Oncology Practice · 2025
- Outcomes of Concurrent Radiotherapy with Tarlatamab in Extensive-Stage Small Cell Lung Cancer from the DLL3 PanTUMOR Database
SSRN Electronic Journal · 2025
- Abstract PS14-06: Real-World Analysis of Adverse Events in Patients with Triple Negative Breast Cancer Receiving Therapy per KEYNOTE-522
Cancer Research · 2024
- Abstract PS14-02: Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522
Cancer Research · 2024
- Outpatient administration of paclitaxel, ifosfamide, and cisplatin (TIP) for germ cell tumor
Journal of Oncology Pharmacy Practice · 2023
- Evaluation of biliary toxicity in patients with hepatic artery infusion pumps
Journal of Oncology Pharmacy Practice · 2023
- Bisphosphonate versus non-bisphosphonate treatment for hypercalcemia of malignancy in patients with renal dysfunction
Journal of Onco-Nephrology · 2023
- Journal of Oncology Pharmacy Practice×4
- Journal of Clinical Oncology×3
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy×2
- Cancer Research×2
- JCO Oncology Practice×2
- Edwin Nieblas‐Bedolla
Medicine · University of Michigan
- Logan Roof
Medicine · The Ohio State University
- Misty Dawn Shields
Medicine · Indiana University
- Jing Su
Medicine · Indiana University
- D. Carbone
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile